Attached files
file | filename |
---|---|
EX-99 - AzurRx BioPharma, Inc. | ex99-04212020_080408.htm |
(Exact name of registrant as specified in its charter.)
(State or other jurisdiction of incorporation or organization)
(IRS Employer Identification No.)
(Address of principal executive offices)
(Registrant's Telephone number)
(Former Name or Former Address, if Changed Since Last Report)
Common Stock, par value $0.0001 per share
AZRX
Nasdaq Capital Market
On April 21, 2020, AzurRx BioPharma, Inc. (the "Company") issued a press release containing a letter addressed to the Company's shareholders and the investment community from the Company's President and Chief Executive Officer, James Sapirstein. A copy of the press release is attached hereto as Exhibit 99.1
This Current Report on Form 8-K and the exhibit attached hereto may contain, among other things, certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, (i) statements with respect to the Company's plans, objectives, expectations and intentions; and (ii) other statements identified by words such as "may", "could", "would", "should", "believes", "expects", "anticipates", "estimates", "intends", "plans" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties.
Press Release issued by the Company, dated April 21, 2020.
Exhibit No.
|
Description
|
|
Press Release issued by AzurRx BioPharma, Inc., dated April 21, 2020
|
AzurRx BioPharma, Inc. |
By: | /s/ James Sapirstein |
Name: James Sapirstein | |
Title: President and Chief Executive Officer |